Leerink Partners on Maze Therapeutics (MAZE): Ph2 results confirm 'best-in-class' profile
Tweet Send to a Friend
Leerink Partners analyst Joseph Schwartz reiterated an Outperform rating and $50.00 price target on Maze Therapeutics (NASDAQ: MAZE)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
